Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
Status:
Recruiting
Trial end date:
2030-10-01
Target enrollment:
Participant gender:
Summary
Difluoromethylornithine (DFMO) will be used in an open label, multicenter, study in
combination with etoposide for subjects with relapsed/refractory neuroblastoma.
Phase:
Phase 2
Details
Lead Sponsor:
Giselle SaulnierSholler Giselle Sholler
Collaborators:
Beat NB Cancer Foundation K C Pharmaceuticals Inc. KC Pharma Team Parker for Life